Development of a Scalable ChiralSynthesis of MK-3281, an Inhibitor of the Hepatitis C Virus NS5BPolymerase

The development of a scalable chiral synthesis for the HCV NS5B inhibitor MK-3281 is being reported. Several alternative routes were explored and are being described.